Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 349

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 349
---
 the amount that fair value is less than the amortized cost basis, are recognized through an allowance for credit losses with changes in the allowance for credit losses recorded in the statements of operations. No impairment losses related to marketable securities have been recognized during the years ended December 31, 2024 and 2023. Any unrealized losses on available-for-saledebt securities that are attributed to credit risk are recorded to earnings through an allowance for credit losses. Unrealized losses on available-for-saledebt securities were not material as of December 31, 2024 and 2023, and no allowance for credit losses was recorded. Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation and amortization expense is recognized using the straight-line method over the following estimated useful lives:

| Asset Category         |     | Estimated Useful Life |
| Leasehold improvements |     | Lease term            |
| Computer equipment     |     | 3 years               |
| Office furniture       |     | 5 years               |

Leases According to ASC 842 Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the use of the identified asset over the term of the arrangement. Right-of-use(“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. To the extent that the Company is unable to utilize an interest rate implicit in the lease, the collateralized incremental borrowing rate is used based on the information available at the lease commencement date, in determining the present value of lease payments. ROU assets are based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and initial direct costs incurred and excludes lease incentives, as applicable. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. F-10

LB Pharmaceuticals Inc

Notes to Financial Statements

The Company has elected to account for lease and non-lease components
together as a single lease component for all underlying assets.

Deferred Offering Costs

The Company capitalizes certain legal, professional and accounting and other third-party fees that are directly associated with
in-process equity financ